Evidence map›Paper›PMID 39614319›Full record

ArticleHarm reduction journal2024

Differences in hepatitis C virus (HCV) testing and treatment by opioid, stimulant, and polysubstance use among people who use drugs in rural U.S. communities.

Angela T Estadt, David Kline, William C Miller, Judith Feinberg, Christopher B Hurt, L Sarah Mixson, Peter D Friedmann, Kelsa Lowe, Judith I Tsui, April M Young and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Harm reduction journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Observational
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Angela T EstadtCollege of Public Health, Division of Epidemiology, Ohio State University, 1841 Neil Avenue, Columbus, OH, 43210, USA. estadt.24@osu.edu.
David KlineDivision of Public Health Sciences, Department of Biostatistics and Data Science, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
William C MillerGillings School of Global Public Health, Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Judith FeinbergDepartments of Behavioral Medicine and Psychiatry & Medicine/Infectious Diseases, West Virginia University School of Medicine, Morgantown, WV, USA.
Christopher B HurtInstitute for Global Health & Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
L Sarah MixsonDepartment of Medicine, University of Washington, Seattle, WA, USA.
Peter D FriedmannUniversity of Massachusetts Medical School-Baystate and Baystate Health, Springfield, MA, USA.
Kelsa LoweDepartment of Medicine, Division of Infectious Disease, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA.
Judith I TsuiDivision of General Internal Medicine, Department of Medicine, University of Washington, Seattle, WA, USA.
April M YoungDepartment of Epidemiology, Center on Drug and Alcohol Research, University of Kentucky, Lexington, KY, USA.
Hannah CooperRollins School of Public Health, Emory University, Atlanta, GA, USA.
P Todd KorthuisDepartment of Medicine, Section of Addiction Medicine, Oregon Health & Science University, Portland, OR, USA.
Mai T PhoDepartment of Medicine, University of Chicago, Chicago, IL, USA.
Wiley JenkinsDepartment of Public Health Sciences, Clemson University, Clemson, SC, USA.
Ryan P WestergaardDepartment of Medicine, Division of Infectious Disease, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA.
Vivian F GoGillings School of Global Public Health, Department of Health Behavior, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Daniel BrookCollege of Medicine, Ohio State University, Columbus, OH, USA.
Gordon SmithDepartment of Epidemiology and Biostatistics, West Virginia University School of Public Health, Morgantown, WV, USA.
Dylan R RiceUniversity of Massachusetts Chan School of Medicine, Worcester, MA, USA.
Kathryn E LancasterDivision of Public Health Sciences, Department of Implementation Science, Wake Forest University School of Medicine, Winston-Salem, NC, USA.

Funding

Ending transmission of HIV, HCV, and STDs and overdose in rural communities of people who inject drugs (ETHIC)UH3DA044829 · NIDA · UNIVERSITY OF CHICAGO · PI JENKINS, WILEY, PHO, MAI TUYET · 2019 to 2022
$5.2M
Peer-based Retention of people who Use Drugs in Rural Research (PROUD-R2)U01TR002631 · NCATS · OREGON HEALTH & SCIENCE UNIVERSITY · PI KORTHUIS, PHILIP TODD, YOUNG, APRIL MARIE · 2018 to 2023
$5.2M
Kentucky Communities and Researchers Engaging to Halt the Opioid Epidemic (CARE2HOPE)UH3DA044798 · NIDA · UNIVERSITY OF KENTUCKY · PI COOPER, HANNAH LF, YOUNG, APRIL MARIE · 2019 to 2022
$4.4M
Oregon HIV/Hepatitis and Opioid Prevention and Engagement (OR-HOPE) Study Cost ExtensionUH3DA044831 · NIDA · OREGON HEALTH & SCIENCE UNIVERSITY · PI KORTHUIS, PHILIP TODD · 2019 to 2022
$4.0M
Drug Injection Surveillance and Care Enhancement for Rural Northern New England (DISCERNNE)UH3DA044830 · NIDA · BAYSTATE MEDICAL CENTER, INC. · PI FRIEDMANN, PETER D, STOPKA, THOMAS J · 2019 to 2022
$3.9M
Spatio-temporal Methods for Surveillance of the Opioid SyndemicR01DA052214 · NIDA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI HEPLER, STACI, KLINE, DAVID M · 2021 to 2025
$3.7M
Rural Comorbidity and HIV consequences of Opioid use Research and Treatment Initiative (Rural cohort)U24DA048538 · NIDA · UNIVERSITY OF WASHINGTON · PI CRANE, HEIDI M., TSUI, JUDITH · 2019 to 2023
$3.7M
Community-based, client-centered prevention homes to address the rural opioid epidemicUH3DA044826 · NIDA · UNIVERSITY OF WISCONSIN-MADISON · PI SEAL, DAVID W, WESTERGAARD, RYAN PATRICK · 2019 to 2022
$2.6M
Learning from the COVID-19 pandemic to improve emergency management planning for harm reduction services in rural OhioUH3DA044822 · NIDA · OHIO STATE UNIVERSITY · PI GO, VIVIAN F., MILLER, WILLIAM C · 2019 to 2022
$2.5M
Off-label Use of Rapid Response Fentanyl Test Strips as an Opioid Overdose Prevention StrategyR01DA047334 · NIDA · RESEARCH TRIANGLE INSTITUTE · PI FEINBERG, JUDITH, ZIBBELL, JON ERIC · 2020 to 2022
$1.9M
Drug Injection Surveillance and Care Enhancement for Rural Northern New England (DISCERNNE)UG3DA044830 · NIDA · BAYSTATE MEDICAL CENTER, INC. · PI FRIEDMANN, PETER D · 2017 to 2018
$1.6M
Community-based, client-centered prevention homes to address the rural opioid epidemicUG3DA044826 · NIDA · UNIVERSITY OF WISCONSIN-MADISON · PI SEAL, DAVID W, WESTERGAARD, RYAN PATRICK · 2017 to 2018
$1.4M
NCATS NIH HHS U01 TR002631NCATS NIH HHS U01TR002631NIDA NIH HHS F30 DA050423NIDA NIH HHS F30DA050423NIDA NIH HHS F31 DA054752NIDA NIH HHS F31DA054752NIDA NIH HHS K01 DA048174NIDA NIH HHS K01DA048174NIDA NIH HHS R01 DA047334NIDA NIH HHS R01DA047334NIDA NIH HHS R01 DA052214NIDA NIH HHS R01DA052214NIDA NIH HHS U24 DA048538NIDA NIH HHS U24DA048538NIDA NIH HHS UG3 DA044798NIDA NIH HHS UG3DA044798/UH3DA044798NIDA NIH HHS UG3 DA044822NIDA NIH HHS UG3DA044822/UH3DA044822NIDA NIH HHS UG3 DA044825NIDA NIH HHS UG3DA044825NIDA NIH HHS UG3 DA044826NIDA NIH HHS UG3DA044826/UH3DA044826NIDA NIH HHS UG3 DA044829NIDA NIH HHS UG3DA044829/UH3DA044829NIDA NIH HHS UG3 DA044830NIDA NIH HHS UG3DA044830/UH3DA044830NIDA NIH HHS UG3 DA044831NIDA NIH HHS UG3DA044831/UH3DA044831NIDA NIH HHS UH3 DA044798NIDA NIH HHS UH3 DA044822NIDA NIH HHS UH3 DA044826NIDA NIH HHS UH3 DA044829NIDA NIH HHS UH3 DA044830NIDA NIH HHS UH3 DA044831
6 · The paper itself

Abstract

backgroundPeople who use drugs (PWUD) in rural communities increasingly use stimulants, such as methamphetamine and cocaine, with opioids. We examined differences in hepatitis C virus (HCV) testing and treatment history among rural PWUD with opioids, stimulants, and other substance use combinations.

methodsPWUD were enrolled from ten rural U.S. communities from 2018 to 2020. Participants self-reporting a positive HCV result were asked about their HCV treatment history and drug use history. Drug use was categorized as opioids alone, stimulants alone, both, or other drug(s) within the past 30 days. Prevalence ratios (PR) were yielded using adjusted multivariable log-binomial regression with generalized linear mixed models.

resultsOf the 2,705 PWUD, most reported both opioid and stimulant use (74%); while stimulant-only (12%), opioid-only (11%), and other drug use (2%) were less common. Most (76%) reported receiving HCV testing. Compared to other drug use, those who reported opioid use alone had a lower prevalence of HCV testing (aPR = 0.80; 95% CI: 0.63, 1.02). Among participants (n = 944) who self-reported an HCV diagnosis in their lifetime, 111 (12%) ever took anti-HCV medication; those who used both opioids and stimulants were less likely to have taken anti-HCV medication compared with other drug(s) (aPR = 0.41; 95% CI: 0.19, 0.91).

conclusionsIn this pre-COVID study of U.S. rural PWUD, those who reported opioid use alone had a lower prevalence of reported HCV testing. Those diagnosed with HCV and reported both opioid and stimulant use were less likely to report ever taking anti-HCV medication.

Indexed as

Rural PopulationSubstance-Related DisordersAdultAnalgesics, OpioidCentral Nervous System StimulantsDrug UsersFemaleHepatitis CHumansMaleMiddle AgedOpioid-Related DisordersPrevalenceUnited StatesYoung AdultAnalgesics, OpioidCentral Nervous System StimulantsHCVOpioidsPolysubstance useRuralStimulants

Identifiers

PMID39614319
PMCPMC11606200

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.